Reviva Pharmaceuticals Holdings, Inc. (RVPH)Healthcare | Biotechnology | Cupertino, United States | OTC Markets OTCQB
0.48 USD
|
Hot Take ↕ | Oct. 10, 2026, 9:22 a.m. EDT
Reviva Pharmaceuticals is a distressed biotech play defined by a catastrophic multi-year decline and a precarious exchange status. The stock has lost over 83% of its value over the last four years, with the last two annual periods showing double-digit contractions, signaling a severe structural deterioration in market valuation. While the balance sheet currently shows low debt relative to cash, the company is burning cash aggressively with negative free cash flow and negative returns on equity, and it faces an imminent delisting from Nasdaq, forcing a transition to the OTC market which typically depresses liquidity and price discovery. The 1-for-20 reverse split is a classic hallmark of a stock struggling to meet minimum listing requirements, often preceding further volatility rather than a recovery. Fundamentally, the business is failing to generate sustainable value, making it a poor long-term hold despite the lofty analyst price targets which ignore the delisting reality. In the short term, the technical picture is weak, trading well below its 200-day average, and the options market is heavily skewed toward downside protection, confirming that smart money is betting against a continued slide or a sharp drop to test critical support levels. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.114278 |
| MSTL | 0.119120 |
| AutoETS | 0.124217 |
| AutoTheta | 0.234300 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 0.12 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.229 |
| Excess Kurtosis | -0.55 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.948 |
| Market Cap | 6,084,929 |
| Forward P/E | -0.56 |
| Beta | 0.48 |
| Website | https://www.revivapharma.com |
As of Oct. 10, 2026, 9:22 a.m. EDT: Speculators are positioning defensively with heavy put volume at deep strikes ($2.00), suggesting a fear of further collapse or a binary event risk, while call interest remains negligible and concentrated only at the money. The implied volatility gap between calls and puts indicates a market pricing in significant downside potential rather than upside speculation.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.9586669 |
| Address1 | 10,080 N. Wolfe Road |
| Address2 | Suite SW3-200 |
| All Time High | 192.2 |
| All Time Low | 0.262 |
| Ask | 0.5248 |
| Ask Size | 2,635 |
| Average Daily Volume10 Day | 36,206 |
| Average Daily Volume3 Month | 34,329 |
| Average Volume | 34,329 |
| Average Volume10Days | 36,206 |
| Beta | 0.48 |
| Bid | 0.475 |
| Bid Size | 16,319 |
| Book Value | 1.16 |
| City | Cupertino |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.475 |
| Current Ratio | 3.563 |
| Custom Price Alert Confidence | LOW |
| Date Short Interest | 1,777,507,200 |
| Day High | 0.475 |
| Day Low | 0.475 |
| Debt To Equity | 0.948 |
| Display Name | Reviva Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda Margins | 0.0 |
| Enterprise Value | -13,518,438 |
| Eps Current Year | -0.85 |
| Eps Forward | -0.85 |
| Eps Trailing Twelve Months | -1.44 |
| Esg Populated | 0 |
| Exchange | OQB |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 408 904 6270 |
| Fifty Day Average | 0.495413 |
| Fifty Day Average Change | -0.020413011 |
| Fifty Day Average Change Percent | -0.041204028 |
| Fifty Two Week Change Percent | -95.86669 |
| Fifty Two Week High | 15.4 |
| Fifty Two Week High Change | -14.924999 |
| Fifty Two Week High Change Percent | -0.96915585 |
| Fifty Two Week Low | 0.262 |
| Fifty Two Week Low Change | 0.213 |
| Fifty Two Week Low Change Percent | 0.81297714 |
| Fifty Two Week Range | 0.262 - 15.4 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,608,042,600,000 |
| Float Shares | 11,861,220 |
| Forward Eps | -0.85 |
| Forward P E | -0.5588235 |
| Free Cashflow | -13,689,651 |
| Full Exchange Name | OTC Markets OTCQB |
| Full Time Employees | 14 |
| Fullday Change | 0.0 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 0.475 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 0 |
| Held Percent Insiders | 0.07727 |
| Held Percent Institutions | 0.08241 |
| Implied Shares Outstanding | 12,810,377 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,773,014,400 |
| Last Split Factor | 1:20 |
| Long Business Summary | Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California. |
| Long Name | Reviva Pharmaceuticals Holdings, Inc. |
| Market | us_market |
| Market Cap | 6,084,929 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_126911636 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -13,022,270 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,292,980 |
| Number Of Analyst Opinions | 2 |
| Open | 0.475 |
| Operating Cashflow | -17,304,396 |
| Operating Margins | 0.0 |
| Phone | 408 501 8881 |
| Previous Close | 0.475 |
| Price Eps Current Year | -0.5588235 |
| Price Hint | 4 |
| Price To Book | 0.40948278 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.352 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 0.475 |
| Regular Market Day Low | 0.475 |
| Regular Market Day Range | 0.475 - 0.475 |
| Regular Market Open | 0.475 |
| Regular Market Previous Close | 0.475 |
| Regular Market Price | 0.475 |
| Regular Market Time | 1,792,157,400 |
| Regular Market Volume | 1 |
| Return On Assets | -0.51404 |
| Return On Equity | -1.76596 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 12,810,377 |
| Shares Percent Shares Out | 0.1457 |
| Shares Short | 1,866,151 |
| Shares Short Previous Month Date | 1,774,915,200 |
| Shares Short Prior Month | 1,834,224 |
| Short Name | Reviva Pharmaceuticals Holdings |
| Short Percent Of Float | 0.1495 |
| Short Ratio | 3.35 |
| Source Interval | 15 |
| State | CA |
| Symbol | RVPH |
| Target High Price | 30.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 17.5 |
| Target Median Price | 17.5 |
| Total Cash | 19,889,960 |
| Total Cash Per Share | 1.517 |
| Total Debt | 144,093 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.44 |
| Trailing Peg Ratio | None |
| Triggerable | 0 |
| Two Hundred Day Average | 1.7006054 |
| Two Hundred Day Average Change | -1.2256054 |
| Two Hundred Day Average Change Percent | -0.7206877 |
| Type Disp | Equity |
| Volume | 1 |
| Website | https://www.revivapharma.com |
| Zip | 95,014 |